PREDICTIVE VALUE FOR TREATMENT OUTCOME IN ACUTE MYELOID-LEUKEMIA OF CELLULAR DAUNORUBICIN ACCUMULATION AND P-GLYCOPROTEIN EXPRESSION SIMULTANEOUSLY DETERMINED BY FLOW-CYTOMETRY

被引:127
作者
GUERCI, A
MERLIN, JL
MISSOUM, N
FELDMANN, L
MARCHAL, S
WITZ, F
ROSE, C
GUERCI, O
机构
[1] CTR ALEXIS VAUTRIN,RECH ONCOL LAB,VANDOEUVRE NANCY,FRANCE
[2] HOP MARIN,SERV EPIDEMIOL MED & STAT,NANCY,FRANCE
关键词
D O I
10.1182/blood.V85.8.2147.bloodjournal8582147
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To evaluate the clinical relevance of multidrug resistance (MDR) phenotype, the intracellular daunorubicin accumulation (IDA) and P-glycoprotein (P-gp) expression were investigated in 87 adult patients with acute leukemia: 69 patients with de novo acute myeloid leukemia (AML), 10 with AML at relapse, and eight with secondary leukemia to myelodysplastic syndromes (MDS-AML). IDA and P-gp expression were determined by double-labeling flow cytometry analysis. Of 87 patients, 36 expressed P-gp (41%), P-gp expression was more frequently observed in AML at relapse and MDS-AML as compared with de novo AML (P = .0001). P-gp expression was significantly associated with CD34 expression (P = .0003) and chromosome 7 abnormalities (P = .027). A significantly reduced IDA was observed in P-gp(+) as compared with P-gp(-) patients (P = .0007). Of the 87 patients, 51 achieved complete remission (CR), A reduced IDA was observed in patients in failure as compared with patients in CR (22% +/- 17% v 42% +/- 21%; P = 10(-4)). Twelve of 36 P-gp(+) patients as compared with 40 of 51 P-gp- patients achieved CR (33% v 78%; P = 10(-4)). The prognostic value of IDA and P-gp expression was confirmed in multivariate analysis. These data suggest that the determination of IDA and P-gp expression may be useful in designing therapy for patients with AML. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:2147 / 2153
页数:7
相关论文
共 48 条
[1]  
BHALLA K, 1985, CANCER RES, V45, P3657
[2]   CLINICOPATHOLOGIC AND CYTOGENIC FEATURES OF CD34 (MY 10)-POSITIVE ACUTE NONLYMPHOCYTIC LEUKEMIA [J].
BOROWITZ, MJ ;
GOCKERMAN, JP ;
MOORE, JO ;
CIVIN, CI ;
PAGE, SO ;
ROBERTSON, J ;
BIGNER, SH .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1989, 91 (03) :265-270
[3]   MECHANISM OF MULTIDRUG RESISTANCE [J].
BRADLEY, G ;
JURANKA, PF ;
LING, V .
BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 948 (01) :87-128
[4]  
BURGER H, 1994, LEUKEMIA, V8, P990
[5]  
CAMPOS L, 1992, BLOOD, V79, P473
[6]  
CAMPOS L, 1992, EUR J HAEMATOL, V48, P254
[7]  
CASS CE, 1989, CANCER RES, V49, P5798
[8]   OVEREXPRESSION OF A TRANSPORTER GENE IN A MULTIDRUG-RESISTANT HUMAN LUNG-CANCER CELL-LINE [J].
COLE, SPC ;
BHARDWAJ, G ;
GERLACH, JH ;
MACKIE, JE ;
GRANT, CE ;
ALMQUIST, KC ;
STEWART, AJ ;
KURZ, EU ;
DUNCAN, AMV ;
DEELEY, RG .
SCIENCE, 1992, 258 (5088) :1650-1654
[9]   DAUNORUBICIN PHARMACOKINETICS AND THE CORRELATION WITH P-GLYCOPROTEIN AND RESPONSE IN PATIENTS WITH ACUTE-LEUKEMIA [J].
GALETTIS, P ;
BOUTAGY, J ;
MA, DDF .
BRITISH JOURNAL OF CANCER, 1994, 70 (02) :324-329
[10]  
GERVASONI JE, 1991, CANCER RES, V51, P4955